Stella Waitere-Wijker
- Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPDBy René Aalbers, M. Reza Maleki-Yazdi, Alan Hamilton, Stella Waitere-Wijker, Anna Pivovarova, Olaf Schmidt and Leif BjermerRené Aalbers1Department of Pulmonary Disease, Martini Hospital, Van Swietenplein 1, Groningen, NetherlandsM. Reza Maleki-Yazdi2Division of Respiratory Medicine, Women's College Hospital, University of Toronto, ON, CanadaAlan Hamilton3Boehringer Ingelheim, Burlington, Ontario, CanadaStella Waitere-Wijker4Boehringer Ingelheim bv, Comeniusstraat 6, Alkmaar, NetherlandsAnna Pivovarova5Boehringer Ingelheim, Pharma GmbH and Co. KG, Biberach, GermanyOlaf Schmidt6Lungen- und Bronchialheilkunde, Emil-Schüller-Straße 29, Koblenz, GermanyLeif Bjermer7Department of Respiratory Medicine and Allergology, Skåne University Hospital, Lund, Sweden
- Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studiesBy Roland Buhl, Roger Abrahams, Leif Bjermer, Eric Derom, Matjaz Flezar, Jacques Hébert, Antony Veale, Lars Groenke, Alan Hamilton, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, Stella Waitere-Wijker and Lorcan McGarveyRoland Buhl1Pulmonary Department, Mainz University Hospital, Mainz, GermanyRoger Abrahams2Pulmonary Department, Morgantown Pulmonary Associates, Morgantown,Leif Bjermer3Department of Respiratory Medicine and Allergology, Lund University, Lund, SwedenEric Derom4Respiratory Division, Ghent University Hospital, Ghent, BelgiumMatjaz Flezar5Respiratory and Allergic Diseases, Klinika Golnik, Golnik, SloveniaJacques Hébert6Centre de Recherche Appliquée en Allergie de Québec, (CRAAQ), Québec, CanadaAntony Veale7Department of Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, AustraliaLars Groenke8Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyAlan Hamilton9Medical, Boehringer Ingelheim, Burlington, CanadaKay Tetzlaff8Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany10Dept of Sports Medicine, Medical Clinic V, University of Tübingen, Tübingen, GermanyLawrence Korducki11Biostatistics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield,Holger Huisman12Medical, Boehringer Ingelheim B.V, Alkmaar, NetherlandsStella Waitere-Wijker12Medical, Boehringer Ingelheim B.V, Alkmaar, NetherlandsLorcan McGarvey13Centre for Infection and Immunity, School of Medicine, Dentistry and BioMedical Sciences, Queen's University Belfast, Belfast, United Kingdom
- Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studiesBy Roland Buhl, Eric Derom, Gary Ferguson, François Maltais, Emilio Pizzichini, Jim Reid, Henrik Watz, Lars Groenke, Alan Hamilton, Kay Tetzlaff, Lawrence Korducki, Holger Huisman, Stella Waitere-Wijker and Eric BatemanRoland Buhl1Pulmonary Department, Mainz University Hospital, Mainz, GermanyEric Derom2Respiratory Division, Ghent University Hospital, Ghent, BelgiumGary Ferguson3Pulmonology Department, Pulmonary Research Institute of Southeast Michigan, Livonia,François Maltais4Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, CanadaEmilio Pizzichini5NUPAIVA (Asthma Research Centre), Universidade Federal de Santa Catarina, Santa Catarina, BrazilJim Reid6Dunedin School of Medicine, University of Otago, Dunedin, New ZealandHenrik Watz7Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, GermanyLars Groenke8Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyAlan Hamilton9Medical, Boehringer Ingelheim, Burlington, CanadaKay Tetzlaff8Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany10Dept of Sports Medicine, Medical Clinic V, University of Tübingen, Tübingen, GermanyLawrence Korducki11Biostatistics, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield,Holger Huisman12Medical, Boehringer Ingelheim B.V., Alkmaar, NetherlandsStella Waitere-Wijker12Medical, Boehringer Ingelheim B.V., Alkmaar, NetherlandsEric Bateman13Division of Pulmonology, University of Cape Town Lung Institute, Cape Town, South Africa
- Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)By Roland Buhl, François Maltais, Roger Abrahams, Leif Bjermer, Eric Derom, Gary Ferguson, Matjaž Fležar, Jacques Hébert, Lorcan McGarvey, Emilio Pizzichini, Jim Reid, Antony Veale, Lars Grönke, Alan Hamilton, Lawrence Korducki, Kay Tetzlaff, Stella Waitere-Wijker, Henrik Watz and Eric BatemanArticle | Published in 2015 in European Respiratory JournalRoland Buhl1Pulmonary Department, Mainz University Hospital, Mainz, GermanyFrançois Maltais2Département de Médecine, Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, CanadaRoger Abrahams3Department of Clinical Research, Morgantown Pulmonary Associates, Morgantown, WV, USALeif Bjermer4Department of Respiratory Medicine and Allergology, Lund University, Lund, SwedenEric Derom5Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumGary Ferguson6Pulmonary Research Institute of Southeast Michigan, Livonia, MI, USAMatjaž Fležar7Klinika Golnik, Golnik, SloveniaJacques Hébert8Department of Medicine, Centre de Recherche Appliquée en Allergie de Québec (CRAAQ), Québec, CanadaLorcan McGarvey9Department of Medicine, Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UKEmilio Pizzichini10Department of Pulmonology, NUPAIVA (Asthma Research Centre), Universidade Federal de Santa Catarina, Santa Catarina, BrazilJim Reid11Dunedin School of Medicine, University of Otago, Dunedin, New ZealandAntony Veale12Department of Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, AustraliaLars Grönke13Department of Medical Affairs Respiratory, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyAlan Hamilton14Medical Department, Boehringer Ingelheim, Burlington, Ontario, CanadaLawrence Korducki15Department of Biostatistics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USAKay Tetzlaff13Department of Medical Affairs Respiratory, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany16Department of Sports Medicine, Medical Clinic V, University of Tübingen, Tübingen, GermanyStella Waitere-Wijker17Medical Department, Boehringer Ingelheim B.V., Alkmaar, The NetherlandsHenrik Watz18Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Grosshansdorf, GermanyEric Bateman19Division of Pulmonology, Department of Medicine, University of Cape Town Lung Institute, Cape Town, South Africa
- Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)By Roland Buhl, François Maltais, Roger Abrahams, Leif Bjermer, Eric Derom, Gary Ferguson, Matjaž Fležar, Jacques Hébert, Lorcan McGarvey, Emilio Pizzichini, Jim Reid, Antony Veale, Lars Grönke, Alan Hamilton, Lawrence Korducki, Kay Tetzlaff, Stella Waitere-Wijker, Henrik Watz and Eric BatemanRoland Buhl1Pulmonary Department, Mainz University Hospital, Mainz, GermanyFrançois Maltais2Département de Médecine, Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, CanadaRoger Abrahams3Department of Clinical Research, Morgantown Pulmonary Associates, Morgantown, WV, USALeif Bjermer4Department of Respiratory Medicine and Allergology, Lund University, Lund, SwedenEric Derom5Department of Respiratory Medicine, Ghent University Hospital, Ghent, BelgiumGary Ferguson6Pulmonary Research Institute of Southeast Michigan, Livonia, MI, USAMatjaž Fležar7Klinika Golnik, Golnik, SloveniaJacques Hébert8Department of Medicine, Centre de Recherche Appliquée en Allergie de Québec (CRAAQ), Québec, CanadaLorcan McGarvey9Department of Medicine, Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UKEmilio Pizzichini10Department of Pulmonology, NUPAIVA (Asthma Research Centre), Universidade Federal de Santa Catarina, Santa Catarina, BrazilJim Reid11Dunedin School of Medicine, University of Otago, Dunedin, New ZealandAntony Veale12Department of Respiratory Medicine, The Queen Elizabeth Hospital, Adelaide, AustraliaLars Grönke13Department of Medical Affairs Respiratory, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyAlan Hamilton14Medical Department, Boehringer Ingelheim, Burlington, Ontario, CanadaLawrence Korducki15Department of Biostatistics, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USAKay Tetzlaff13Department of Medical Affairs Respiratory, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany16Department of Sports Medicine, Medical Clinic V, University of Tübingen, Tübingen, GermanyStella Waitere-Wijker17Medical Department, Boehringer Ingelheim B.V., Alkmaar, The NetherlandsHenrik Watz18Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Grosshansdorf, GermanyEric Bateman19Division of Pulmonology, Department of Medicine, University of Cape Town Lung Institute, Cape Town, South Africa
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.